Doubts on ChemoCentryx's diabetic nephropathy study trigger plunge

Shares of ChemoCentryx ($CCXI) tanked this morning after the biotech released weak interim results for its mid-stage study on a new drug for diabetic nephropathy. The company says the chemokine receptor CCX140 spurred a significant reduction in proteinuria after 12 weeks of therapy, spurring some confident remarks from executives. But some analysts said the drug was not clearly better than a placebo, prompting a 23% plunge in the stock price. A few weeks ago another one of the Mountain View, CA-based biotech's drugs outlicensed to GlaxoSmithKline ($GSK) for Crohn's disease failed the first of four late-stage studies. Release

Suggested Articles

Karen DeSalvo's appointment is the latest in a string of hires that deepen the tech giant’s investment in and focus on healthcare.

Spring Bank’s hepatitis B drug, given in tandem with Gilead’s Vemlidy, tamped down on chronic disease in 23% of patients in a phase 2 study.

Gilead names Dickinson to CFO role; MedImmune CSO Herbst nabs CSO job at Pyxis; Checkmate picks up Wooldridge for CMO.